Cells to Society: Uncommon insights to understanding, treating and preventing common cancers
Living At Your Peak
Dr. Eric R. Fearon, M.D., Ph.D.
Dr. Scott Tomlins, M.D., Ph.D.
Dr. Kathleen R. Cho, M.D.
Dr. Elizabeth Lawlor, M.D., Ph.D.
Dr. Sofia Diana Merajver, M.D.
Saturday, August 19, 2017
2 p.m. to 5:30 p.m.
Edwards Interfaith Chapel | Edwards, Colorado
CANCER. It’s the disease Americans fear most, the disease we most want to cure. It can be devastating for a patient, a family, or a community, instantly reminding us how precious life is and inspiring us to rally around a common goal.
Research advances over the past three decades have yielded great successes in improving patient survival and in achieving cures for common cancers such as breast cancer, ovarian cancer, lung cancer, esophageal cancer and prostate cancer.
With the rare opportunity to host five specialists from the University of Michigan Comprehensive Cancer Center (UMCCC), the Vail Symposium will present a two-part panel program where everyone–medical doctors and patients to those simply interested in learning about measures of treatment and prevention of common cancers–can grasp exciting new breakthroughs in cancer research.
Part 1 – 2 pm – 3:30 pm
30-minute break with refreshments and an opportunity for the audience to interact with the panelist
Part 2 – 4 pm to 5:30 pm
There will be a 30-minute reception following part 2 where the audience will have the opportunity to interact with the panelists.
MEET THE PANEL
Dr. Eric Fearon was named Director at the UMCCC in September of 2016. He is a Professor of Oncology and also a Professor in the Departments of Internal Medicine, Human Genetics, and Pathology at the University of Michigan Medical School. Dr. Fearon has authored more than 135 peer-reviewed research manuscripts and more than 60 review/editorial articles and book chapters. He has pursued research in the cancer genetics field, particularly investigations of selected gene defects that underlie colon and rectal tumor development and progression to advanced stages. He is currently an editorial board member or editor at 10 journals, including The Journal of Biological Chemistry, Current Biology, Journal of Clinical Investigation, and Gastroenterology.
Dr. Scott Tomlins obtained his M.D. and Ph.D. at the University of Michigan Medical School. His thesis described the identification and characterization of recurrent ETS gene fusions in prostate cancer. He completed residency in Anatomic Pathology at U-M and is an Assistant Professor of Pathology and Urology and a member of the Michigan Center for Translational Pathology. Dr. Tomlins has co-authored more than 100 manuscripts, focusing on the integrative analysis, functional characterization and clinical translation of cancer genomics and is developing broadly applicable personalized medicine approaches to prostate cancer early detection, prognosis and treatment of advanced disease.
Specialty: Prostate Cancer
Dr. Kathleen R. Cho is the head of the gynecologic pathology section of Surgical Pathology at the University of Michigan Health System. Dr. Cho has established a research laboratory that uses a range of systems and approaches to study the molecular pathogenesis of ovarian cancers. These include technologies to generate comprehensive molecular profiles of primary human carcinomas and their precursors, in vitro systems to study altered signaling pathways and effects of specific molecular alterations in cancer cells, and genetically engineered mouse models of cancer.
Specialty: Ovarian Cancer
Dr. Elizabeth Lawlor, associate director for education and training, is the Russell G. Adderley Professor of Pediatric Oncology Research and an associate professor in the departments of Pediatrics and Pathology at the University of Michigan Medical School. She received her medical degree from McMaster University in Ontario, Canada, and her doctorate in cancer biology from the University of British Columbia in Vancouver, Canada. She completed clinical and research fellowships in pediatric hematology/oncology and bone marrow transplantation at British Columbia Children’s Hospital, and post-doctoral training at the University of California San Francisco Cancer Research Institute. She joined the University of Michigan faculty in 2010 from Children’s Hospital Los Angeles and the University of Southern California. Lawlor’s research focuses on understanding how hijacking of normal stem cell and developmental processes contributes to the initiation and progression of Ewing sarcoma.
Dr. Sofia Diana Merajver, an expert in breast cancer genetics, is the medical director of the Breast and Ovarian Cancer Risk Evaluation Program at the U-M Cancer Center. Dr. Sofia Merajver received a doctoral degree in physics from the University of Maryland and a medical degree from the University of Michigan. She completed a residency in internal medicine and a fellowship in oncology at the University of Michigan before joining the faculty in 1994. Her research interests include the molecular genetics of breast cancer, gene function and cancer risk assessment.
Specialty: Breast Cancer
CONNECT WITH UMCCC
Let the Antlers at Vail take care of you.
The Antlers at Vail has been the signature hotel partner of the Vail Symposium since 2003, housing hundreds of prominent speakers from around the world. From U.S. Senators and Congressman to renowned entertainers and authors, the Antlers has taken the best care of anyone associated with the Vail Symposium. Located steps from the Lionshead Gondola and Vail’s best bars and restaurants, let the Antlers take care of you.